Could a repurposed drug boost immune attack on childhood brain tumors?
NCT ID NCT05106296
First seen Jan 11, 2026 · Last updated Jun 18, 2026 · Updated 24 times
Summary
This early-phase trial is testing whether adding the drug ibrutinib to a chemo-immunotherapy regimen can safely help children and young adults (ages 6–25) with brain cancers that have come back or not responded to standard treatment. The study combines ibrutinib with indoximod and two chemotherapy drugs to try to boost the immune system's ability to fight the tumor. The main goals are to find the best safe dose and to see if the combination shrinks tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Augusta University, Georgia Cancer Center
RECRUITINGAugusta, Georgia, 30912, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.